Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Phase I Study to Assess the Safety of NKR-2 Treatment Administration After a Non-myeloablative Preconditioning Chemotherapy in Relapse/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients.

Trial Profile

An Open-label, Phase I Study to Assess the Safety of NKR-2 Treatment Administration After a Non-myeloablative Preconditioning Chemotherapy in Relapse/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Feb 2019

At a glance

  • Drugs CYAD 01 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Acronyms DEPLETHINK
  • Sponsors Celyad
  • Most Recent Events

    • 04 Dec 2018 Results of THINK, DEPLETHINK and EPITHINK trials assessing safety and clinical activity of multiple doses of Cyad-01, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
    • 04 Dec 2018 Results presented in the Celyad media release.
    • 04 Dec 2018 According to a Celyad media release, data from this trial were presented at the American Society of Hematology (ASH) 60th Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top